Table 1 Criteria for setting priorities according to their assessed importance by participants and external stakeholders.
From: Prioritization strategies in clinical practice guidelines development: a pilot study
Domain | Items | Mean participants' weighted score (SD) |
|---|---|---|
Disease Burden | - Disease/Condition incidence or prevalence - High risk impact of disease/condition in the health system - High frequency of risk factors associated with the disease/condition - High frequency of avoidable risk factors associated with the disease/condition | 80,8 (18,2) |
Information needs in the Health Sector | - Information needs within the Institution/Organization - Current controversy about topic importance - High importance of new methods and technology assessment - Fast diffusion of non-assessed technologies, availability of resources and sufficient time for technologies implementation - Country health priorities in agreement with CPG's needs - High impact on national health system | 74,7 (18,1) |
Feasibility on development and implementation | - Feasibility on recommendations development which will improve health outcomes and cost - Is the proposal politically feasible? - Does it belong to priority health areas according to government policies? - Feasibility in implementation; will not require an excessive amount of resources and will not present important barriers to implement changes - Will reduce inequities when implemented - Will require education to training professionals - Does the proposed topic include the participation of multiple departments, institutions, organizations, etc? | 72,7 (17,1) |
Effectiveness | - Availability of effective methods shown by methodologically adequate studies. - Certainty about effectiveness of assessed interventions and technologies - Potential impact of CPG | 71,2 (20,7) |
Economic impact on the health system | - Economic effects on health system (cost of an individual patient is high during diagnosis or therapeutic process) - Disease/Condition associated with iatrogenic interventions that are significantly high in cost. | 69,8 (24,0) |
Clinical Practice Variation | - Current evidence is insufficient for disease control in the population - Lack of high quality CPGs - Availability of high volume of evidence regarding the CPG topic - Evidence of inappropriate use of available technologies used in the treatment of condition (iatrogenic) - Conditions/diseases where effective treatments could reduce mortality or morbidity - Evidence of disagreements between current treatment and literature recommendations. | 68,0 (22,1) |
Other social effects/Equity | - Absenteeism from work or school, inability to work, inequities in access to health services - Will the service be available to anyone who requires it? - Will this CPG have a positive or negative impact on minorities' access to health services? - Will the CPG increase health service access to those affected by the condition? | 67,2 (25,7) |
User Preferences | - High patient demand or interest - Concerns about patients' quality of life - Feasibility of patient empowerment - High acceptability of the topic between the general public and professionals affected by the use of the CPG. | 64,9 (22,3) |
Adverse events | - Possibility of adverse events - Possibility of serious adverse events - Disease/condition associated with high incidence of adverse events or sequels | 57,1 (28,0) |
Health Promotion and Disease Prevention | - Feasibility of prevention between patients with risk factors - Are there specific activities of health promotion, disease prevention, early diagnosis or treatment? Have all of them shown a reduction in disease burden? | 56,4 (32,3) |